WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522374

CAS#: 426268-06-6

Description: ABE171, also known as NVP-ABE171, is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities. NVP-ABE171 inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D with respective IC(50) values of 602, 34, 1230, and 1.5 nM. In human cells, NVP-ABE171 inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and the tumor necrosis factor-alpha release from monocytes, in the nanomolar range. NVP-ABE171 inhibited the airway neutrophil influx and activation with an ED(50) in the range of 3 mg/kg. NVP-ABE171 shows activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation.

Chemical Structure

CAS# 426268-06-6

Theoretical Analysis

MedKoo Cat#: 522374
Name: ABE171
CAS#: 426268-06-6
Chemical Formula: C21H12N4O3
Exact Mass: 368.09094
Molecular Weight: 368.35
Elemental Analysis: C, 68.48; H, 3.28; N, 15.21; O, 13.03

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: ABE171; ABE-171; ABE 171; NVP-ABE171; NVP-ABE-171; NVP-ABE 171.

IUPAC/Chemical Name: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid


InChi Code: InChI=1S/C21H12N4O3/c26-21(27)13-5-3-12(4-6-13)17-10-14-2-1-9-22-19(14)20(23-17)15-7-8-16-18(11-15)25-28-24-16/h1-11H,(H,26,27)

SMILES Code: O=C(O)C1=CC=C(C2=NC(C3=CC4=NON=C4C=C3)=C5N=CC=CC5=C2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 368.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W,
Beebe DJ, Marker PC. Phosphodiesterase 4D inhibitors limit prostate cancer growth
potential. Mol Cancer Res. 2015 Jan;13(1):149-60. doi:
10.1158/1541-7786.MCR-14-0110. Epub 2014 Aug 22. PubMed PMID: 25149359; PubMed
Central PMCID: PMC4312503.

2: Tigani B, Cannet C, Zurbrugg S, Schaeublin E, Mazzoni L, Fozard JR, Beckmann
N. Resolution of the oedema associated with allergic pulmonary inflammation in
rats assessed noninvasively by magnetic resonance imaging. Br J Pharmacol. 2003
Sep;140(2):239-46. Epub 2003 Aug 18. PubMed PMID: 12970099; PubMed Central PMCID:

3: Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R. Pharmacological
profile of a novel phosphodiesterase 4 inhibitor,
4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid
(NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.
J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. PubMed PMID: 11907180.


10.0mg / Not available